Skip to content
You can now search across every topic, entity and event.What's new
RA Capital Management
OrganisationUS

RA Capital Management

Boston crossover biotech fund; co-invested in CellCentric's £170m Series D.

Last refreshed: 13 May 2026 · Appears in 1 active topic

Timeline for RA Capital Management

View full timeline →
Follow Drones: Industry & Defence →
Common Questions
What is RA Capital Management?
RA Capital is a Boston crossover biotech investment firm founded in 2001, investing in clinical-stage life sciences from private rounds through post-IPO, with a focus on oncology and immunology.Source: RA Capital
Why is RA Capital investing in UK biotech?
RA Capital participated in CellCentric's £170m Series D in May 2026. Its crossover model allows it to hold European biotech positions from late-stage private financing through a future IPO.Source: Lowdown uk-startups-and-innovation U#4

Background

RA Capital Management participated in CellCentric's £170m Series D in May 2026, Europe's largest biotech round of the year, alongside Venrock Healthcare, Pfizer, Fidelity, Sofinnova Partners, HBM Healthcare, and others. CellCentric's Phase III programme for inobrodib in multiple myeloma sits squarely within RA Capital's oncology crossover thesis.

RA Capital Management is a Boston-based healthcare investment firm founded in 2001, focused on life sciences and biotech at the intersection of private and public markets — the classic 'crossover' model. It manages multiple funds including a hedge fund and private VC vehicles, enabling it to hold positions from private financing through post-IPO. RA Capital is known for large concentrated bets in clinical-stage oncology and immunology, and has a deep scientific team that underwrites late-stage clinical risk directly. Its participation in non-US rounds signals its view that European biotech at clinical stage is attractively priced relative to US comparables.